|Bid||1.6800 x 1800|
|Ask||1.6900 x 1300|
|Day's Range||1.6620 - 1.7800|
|52 Week Range||1.5200 - 2.9600|
|Beta (5Y Monthly)||1.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.67|
DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed research paper describing the binding sites and proposed mechanism of action of its lead drug candidate, an endogenous sulfated oxysterol and epigenetic regulator, DUR-928, in The Journal of Lipid Research.
Shares of Durect (NASDAQ:DRRX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 100.00% year over year to ($0.04), which missed the estimate of ($0.03). Revenue of $2,207,000 declined by 79.34% year over year, which missed the estimate of $6,570,000. Guidance Durect hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. Conference Call Details Date: Mar 04, 2021 View more earnings on DRRX Time: 04:30 PM ET Webcast URL: http://public.viavid.com/player/index.php?id=143367 Technicals Company's 52-week high was at $2.96 Company's 52-week low was at $0.95 Price action over last quarter: Up 24.85% Company Profile Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, Remoxy, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For March 4, 2021© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Durect (DRRX) delivered earnings and revenue surprises of -33.33% and -66.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?